Login
$VBIO
$0.55 +$0.02 (4.18%) After hours

$VBIO SEC Filings

Filed On Filing
16 Nov 2026 NT 10-Q
12 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Fifth Side Letter — Closing under Series B Preferred Purchase Agreement

05 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation
02 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Certain personal information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. The omitted information is indicated by “[***]”

29 Oct 2026 8-K: Other Events

Valion Bio Announces Positive Safety Results from U.S. Government-Funded Entolimod Study, Paving Way for Therapeutic Efficacy Evaluation

27 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Re: Fourth Side Letter — Closing under Series B Preferred Purchase Agreement

26 Oct 2026 8-K: Other Events

Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod

22 Oct 2026 8-K: Other Events

Interim CEO Dean Zikria’s initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company’s integrated capabilities

20 Oct 2026 EFFECT
20 Oct 2026 EFFECT
21 Oct 2026 424B3
16 Oct 2026 REGISTRATION STATEMENT
16 Oct 2026 DEFINITIVE PROXY STATEMENT
15 Oct 2026 8-K: Other Events

Velocity Bioworks successfully completes initial evaluation of LarmorBio’s BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, vi...

14 Oct 2026 8-K: Other Events

With Section 232 Tariffs Reshaping Biotech, Valion Bio’s Velocity Bioworks Capitalizes on Domestic CDMO Surge

08 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Third Side Letter — Closing under Series B Preferred Purchase Agreement

08 Oct 2026 REGISTRATION STATEMENT
06 Oct 2026 8-K: Other Events

Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing

05 Oct 2026 DRS

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support